Dr. Vinay Prasad to Depart FDA Amid Controversial Tenure
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy MRNA?
Source: Benzinga
- Leadership Change: Dr. Vinay Prasad, head of the FDA's Center for Biologics Evaluation and Research, is set to leave at the end of April, which may impact the agency's policy direction on vaccines and biotech drugs, particularly as new policies he implemented are still unfolding.
- Controversial Tenure: Prasad's tenure has been contentious, marked by staff complaints about his management style; however, his rehiring in August 2025 indicates a divide within the FDA regarding his leadership, potentially affecting the agency's stability.
- Vaccine Standards Reform: His departure follows strict reforms in vaccine standards at the FDA, sparking widespread industry debate that could have lasting implications for future vaccine approval processes, especially given his critical stance on the biopharmaceutical industry.
- Regulatory Direction Debate: Prasad's return ignited discussions about the FDA's regulatory direction, particularly due to his criticisms of certain FDA approval pathways, which may lead to decreased confidence in the agency's future policies and impact strategic planning for biopharmaceutical companies.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MRNA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MRNA
Wall Street analysts forecast MRNA stock price to fall
20 Analyst Rating
1 Buy
16 Hold
3 Sell
Hold
Current: 53.830
Low
17.00
Averages
32.47
High
63.00
Current: 53.830
Low
17.00
Averages
32.47
High
63.00
About MRNA
Moderna, Inc. is a biotechnology company. The Company is advancing a new class of medicines made of messenger ribonucleic acid (mRNA). It is developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane or secreted proteins that have a therapeutic or preventive benefit with the potential to address a spectrum of diseases. The Company’s diverse development pipeline consists of 44 therapeutic and vaccine programs, 11 of which are in late-stage development. Its commercial products include Spikevax (its COVID vaccine) and mRESVIA (its respiratory syncytial virus (RSV) vaccine). Additionally, it has achieved four positive Phase III data readouts for its COVID vaccine (mRNA-1283), its RSV vaccine for high-risk adults aged 18 to 59 (mRNA-1345), its seasonal flu+COVID vaccine (mRNA-1083), and its seasonal flu vaccine (mRNA-1010).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Dr. Vinay Prasad to Depart FDA Amid Controversial Tenure
- Leadership Change: Dr. Vinay Prasad, head of the FDA's Center for Biologics Evaluation and Research, is set to leave at the end of April, which may impact the agency's policy direction on vaccines and biotech drugs, particularly as new policies he implemented are still unfolding.
- Controversial Tenure: Prasad's tenure has been contentious, marked by staff complaints about his management style; however, his rehiring in August 2025 indicates a divide within the FDA regarding his leadership, potentially affecting the agency's stability.
- Vaccine Standards Reform: His departure follows strict reforms in vaccine standards at the FDA, sparking widespread industry debate that could have lasting implications for future vaccine approval processes, especially given his critical stance on the biopharmaceutical industry.
- Regulatory Direction Debate: Prasad's return ignited discussions about the FDA's regulatory direction, particularly due to his criticisms of certain FDA approval pathways, which may lead to decreased confidence in the agency's future policies and impact strategic planning for biopharmaceutical companies.
See More
FDA Vaccine Chief Vinay Prasad to Depart Agency
- Departure Sparks Market Reaction: FDA vaccine chief Vinay Prasad is set to leave at the end of April, with shares of Moderna (MRNA) rising 3%, uniQure (QURE) soaring 50%, and Sarepta Therapeutics (SRPT) gaining 5% in after-hours trading, indicating a positive market response to his exit.
- Controversial Tenure: During his time, Prasad faced disputes, notably refusing to consider Moderna's flu vaccine application, although the FDA later reversed its stance after Moderna agreed to conduct a follow-up study, highlighting the complexities of his drug review process.
- FDA Scrutiny on uniQure: The FDA recently recommended that uniQure conduct a sham-surgery-controlled study for its gene therapy targeting Huntington's disease, illustrating the challenges Prasad faced in drug evaluations and the tension with companies affecting their R&D timelines.
- Policy Implementation Completed: Prasad's departure is attributed to the completion of all policies he aimed to implement, including a new priority program to expedite application reviews for treatments meeting national priorities, indicating that his objectives at the FDA have largely been achieved.
See More
FDA Vaccine and Biotech Chief Resigns Amid Industry Criticism
- Regulatory Uncertainty Intensifies: Vinay Prasad, director of the FDA's Center for Biologics Evaluation and Research, will resign at the end of April amid widespread criticism from the biotech and pharmaceutical industries for denying or hindering at least eight drug approval applications, potentially stifling new drug development.
- Strong Industry Backlash: Prasad's resignation highlights a crisis of trust within the FDA's drug approval process, particularly as companies express confusion and dissatisfaction with the agency's guidance, which may impact future drug research and development.
- Pressure for Internal Reform: Under Health and Human Services Secretary Robert F. Kennedy Jr., the FDA has undergone staff cuts and restructuring, further exacerbating external doubts about its drug and vaccine approval processes, which could jeopardize patient safety.
- Successor Yet to Be Named: FDA Commissioner Marty Makary stated that a successor will be appointed before Prasad's departure, and while Prasad achieved certain accomplishments during his tenure, his resignation may affect the FDA's future decisions and industry confidence.
See More
FDA Rejects Multiple Experimental Drug Applications, Raising Investor Concerns
- FDA Drug Rejections: The U.S. FDA has denied or discouraged applications for at least eight drugs over the past year, including UniQure's gene therapy for Huntington's disease, indicating regulatory uncertainty that could impact future treatment approvals.
- Investor Concerns Rise: Investors are increasingly wary as the FDA appears to change its standards for drug applications, particularly for treatments targeting hard-to-treat diseases, leading to diminished confidence in ongoing development efforts.
- Changing Regulatory Standards: The FDA's request for UniQure to conduct new placebo-controlled trials contradicts previous guidance, highlighting inconsistencies in the agency's approval process that may create uncertainty for companies in their R&D efforts.
- Uncertain Future Outlook: Analysts warn that if the FDA does not approve Denali Therapeutics' drug for Hunter syndrome, it could further undermine other companies' confidence in running open-label studies, potentially stifling innovation across the industry.
See More
FDA Drug Approval Uncertainty Intensifies
- Drug Applications Denied: According to RTW Investments, the FDA has denied or discouraged applications for at least eight new drugs over the past year, including gene therapies for Huntington's and Hunter syndrome, raising investor concerns about the prospects for other drugs in the pipeline.
- Changing Regulatory Standards: The FDA's request for UniQure to conduct new placebo-controlled studies contradicts previous guidance, leading investors to doubt the agency's consistency and fearing that this could jeopardize future treatment approvals.
- Negative Market Reaction: Stocks of several biotech companies have declined following FDA rejections, with analysts noting a stark conflict between the FDA's recent decisions and the flexibility promised by its leadership, causing investors to lose confidence in companies relying on FDA leniency.
- Uncertain Future Outlook: Although FDA officials assert that biomarkers can lead to accelerated approvals, investors remain confused about the agency's approval standards, particularly for drugs targeting rare diseases, making future approval pathways increasingly uncertain.
See More
Stocks Recover Losses from Iran
- Market Reaction: The S&P 500 index has returned to its previous levels prior to the attacks in Iran.
- Impact of Events: The market's recovery indicates resilience despite geopolitical tensions.
See More
Dr. Vinay Prasad to Depart FDA Amid Controversial Tenure
- Leadership Change: Dr. Vinay Prasad, head of the FDA's Center for Biologics Evaluation and Research, is set to leave at the end of April, which may impact the agency's policy direction on vaccines and biotech drugs, particularly as new policies he implemented are still unfolding.
- Controversial Tenure: Prasad's tenure has been contentious, marked by staff complaints about his management style; however, his rehiring in August 2025 indicates a divide within the FDA regarding his leadership, potentially affecting the agency's stability.
- Vaccine Standards Reform: His departure follows strict reforms in vaccine standards at the FDA, sparking widespread industry debate that could have lasting implications for future vaccine approval processes, especially given his critical stance on the biopharmaceutical industry.
- Regulatory Direction Debate: Prasad's return ignited discussions about the FDA's regulatory direction, particularly due to his criticisms of certain FDA approval pathways, which may lead to decreased confidence in the agency's future policies and impact strategic planning for biopharmaceutical companies.
See More
FDA Vaccine Chief Vinay Prasad to Depart Agency
- Departure Sparks Market Reaction: FDA vaccine chief Vinay Prasad is set to leave at the end of April, with shares of Moderna (MRNA) rising 3%, uniQure (QURE) soaring 50%, and Sarepta Therapeutics (SRPT) gaining 5% in after-hours trading, indicating a positive market response to his exit.
- Controversial Tenure: During his time, Prasad faced disputes, notably refusing to consider Moderna's flu vaccine application, although the FDA later reversed its stance after Moderna agreed to conduct a follow-up study, highlighting the complexities of his drug review process.
- FDA Scrutiny on uniQure: The FDA recently recommended that uniQure conduct a sham-surgery-controlled study for its gene therapy targeting Huntington's disease, illustrating the challenges Prasad faced in drug evaluations and the tension with companies affecting their R&D timelines.
- Policy Implementation Completed: Prasad's departure is attributed to the completion of all policies he aimed to implement, including a new priority program to expedite application reviews for treatments meeting national priorities, indicating that his objectives at the FDA have largely been achieved.
See More
FDA Vaccine and Biotech Chief Resigns Amid Industry Criticism
- Regulatory Uncertainty Intensifies: Vinay Prasad, director of the FDA's Center for Biologics Evaluation and Research, will resign at the end of April amid widespread criticism from the biotech and pharmaceutical industries for denying or hindering at least eight drug approval applications, potentially stifling new drug development.
- Strong Industry Backlash: Prasad's resignation highlights a crisis of trust within the FDA's drug approval process, particularly as companies express confusion and dissatisfaction with the agency's guidance, which may impact future drug research and development.
- Pressure for Internal Reform: Under Health and Human Services Secretary Robert F. Kennedy Jr., the FDA has undergone staff cuts and restructuring, further exacerbating external doubts about its drug and vaccine approval processes, which could jeopardize patient safety.
- Successor Yet to Be Named: FDA Commissioner Marty Makary stated that a successor will be appointed before Prasad's departure, and while Prasad achieved certain accomplishments during his tenure, his resignation may affect the FDA's future decisions and industry confidence.
See More
FDA Rejects Multiple Experimental Drug Applications, Raising Investor Concerns
- FDA Drug Rejections: The U.S. FDA has denied or discouraged applications for at least eight drugs over the past year, including UniQure's gene therapy for Huntington's disease, indicating regulatory uncertainty that could impact future treatment approvals.
- Investor Concerns Rise: Investors are increasingly wary as the FDA appears to change its standards for drug applications, particularly for treatments targeting hard-to-treat diseases, leading to diminished confidence in ongoing development efforts.
- Changing Regulatory Standards: The FDA's request for UniQure to conduct new placebo-controlled trials contradicts previous guidance, highlighting inconsistencies in the agency's approval process that may create uncertainty for companies in their R&D efforts.
- Uncertain Future Outlook: Analysts warn that if the FDA does not approve Denali Therapeutics' drug for Hunter syndrome, it could further undermine other companies' confidence in running open-label studies, potentially stifling innovation across the industry.
See More
FDA Drug Approval Uncertainty Intensifies
- Drug Applications Denied: According to RTW Investments, the FDA has denied or discouraged applications for at least eight new drugs over the past year, including gene therapies for Huntington's and Hunter syndrome, raising investor concerns about the prospects for other drugs in the pipeline.
- Changing Regulatory Standards: The FDA's request for UniQure to conduct new placebo-controlled studies contradicts previous guidance, leading investors to doubt the agency's consistency and fearing that this could jeopardize future treatment approvals.
- Negative Market Reaction: Stocks of several biotech companies have declined following FDA rejections, with analysts noting a stark conflict between the FDA's recent decisions and the flexibility promised by its leadership, causing investors to lose confidence in companies relying on FDA leniency.
- Uncertain Future Outlook: Although FDA officials assert that biomarkers can lead to accelerated approvals, investors remain confused about the agency's approval standards, particularly for drugs targeting rare diseases, making future approval pathways increasingly uncertain.
See More
Stocks Recover Losses from Iran
- Market Reaction: The S&P 500 index has returned to its previous levels prior to the attacks in Iran.
- Impact of Events: The market's recovery indicates resilience despite geopolitical tensions.
See More
